Carolyn Bernstein, MD
Neurology · Brookline, MANPI 1083782981
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,169 of the $12,477 with a category attached, or 97.5%. Teva Pharmaceuticals USA, Inc. accounts for 63.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $6,950 and has fallen 98.4% since, to $109 in 2024.
Across 15 payments — averaging $831.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$8K
- Amgen$4K
- Lundbeck LLC$54
- Novartis$39
Across 13 payments — averaging $39,101 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$504K
- Amgen$4K
What the payments were for
- Consulting fees$12,16998%
- Food & beverage$3072%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $7,961 |
| Amgen | 9 | $4,423 |
| Lundbeck LLC | 1 | $54 |
| Novartis | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,477 in reported general payments places this provider in the 80th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 28 | $54,889 |
| UbrelvyUbrogepant | 53 | $53,082 |
| QuliptaAtogepant | 17 | $35,681 |
| Ajovy SyringeFremanezumab-Vfrm | 28 | $30,591 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 32 | $29,523 |
| Emgality PenGalcanezumab-Gnlm | 27 | $23,682 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $19,298 |
| ReyvowLasmiditan Succinate | 19 | $15,704 |
| Sumatriptan Succinate | 78 | $3,535 |
| Candesartan Cilexetil | 22 | $2,545 |
| RizatriptanRizatriptan Benzoate | 85 | $1,701 |
| Naratriptan Hcl | 60 | $1,668 |
| Eletriptan HbrEletriptan Hydrobromide | 14 | $908 |
| Topiramate | 53 | $740 |
| Gabapentin | 76 | $683 |
Paid to pharmacies, not to this prescriber.
Other neurology in Brookline
- Guy BuckleBrookline$450K
- Maria HoutchensBrookline$259K
- Rohit BakshiBrookline$196K
- James StankiewiczBrookline$122K
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.